Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitGlobeNewsWire • Thursday
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh NegativesSeeking Alpha • 09/12/24
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling DrugBenzinga • 09/11/24
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare ConferenceGlobeNewsWire • 08/28/24
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDAGlobeNewsWire • 08/19/24
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?Zacks Investment Research • 08/09/24
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/07/24
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024GlobeNewsWire • 07/23/24
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 NamesInvestorPlace • 07/19/24
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/30/24
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in EpilepsyGlobeNewsWire • 05/23/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNPRNewsWire • 05/23/24
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresGlobeNewsWire • 05/09/24
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/09/24
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 05/07/24
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaPRNewsWire • 05/07/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsBusiness Wire • 05/02/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsBusiness Wire • 05/02/24